수모세포종 치료후 발생한 척추골절에서 파미드로네이트 치료 1례 = Pamidronate Treatment in Vertebral Fracture after Off-therapy of Medulloblastoma

다국어 초록 (Multilingual Abstract)

A twenty-one year old man, who had been treated for medulloblastoma 6 years ago, complained progressive right knee joints pain and back pain. Multiple thoracic vertebral compression fracture was detected in radiography. The bone mineral density(BMD) was in osteoporotic range in duel energy X- ray absorpometry. Growth hormone deficiency and primary hypothyroidism were detected after endocrine function test. We treated him by cyclic intravenous pamidronate because he had complained severe back pain and difficulty to walk. After pamidronate therapy, the pain was decreased and the BMD was increased. No severe adverse effect was noted. This is the first case report of pamidronate therapy in patient who had osteoporotic vertebral compression fracture due to a sequela of childhood medulloblastoma.

국문 초록 (Abstract)

소아기에 발생한 수모세포종에서 골다공증의 발생률은 매우 높으며, 이는 대개 성장호르몬 결핍증이 그 주요 원인이다. 수모세포종 치료 후 정기적으로 성장호르몬 결핍 여부와 골다공증의 발생여부를 추적 관찰하는 것은 매우 중요하다. 골절이 동반되어 심한 통증을 호소하고 운동능력이 제한된 환자에서 파미드로네이트의 치료는 통증을 조절하고 골밀도를 증가시키며 삶의 질을 증진시킨다. 저자들은 척추골절을 보인 수모세포종 환자에서 파미드로네이트를 사용한 환자 1례를 문헌 고찰과 함께 보고하는 바이다.

참고문헌 (Reference)

1 윤인석, "소아 수모세포종 환자에서 치료 후의 내분비적 장애와 성장변화" 대한소아과학회 49 (49): 292-297, 2006

2 Amin S, "The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach." 42 : 1740-1751, 1999

3 Mithal N.P, "Reduced bone mineral density in long-term survivors of medulloblastoma." 66 : 814-816, 1993

4 Geusens P, "Recovery from severe glucocorticoid-induced osteoporosis in an adolescent boy." 4 : 389-394, 2001

5 Zacharin M, "Pamidronate treatment of osteogenesis imperfecta: lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response." 15 : 163-174, 2002

6 Goldbloom E.B, "Osteoporosis at presentation of childhood ALL: management with pamidronate." 22 : 543-550, 2005

7 Gilsanz V, "Osteoporosis after cranial irradiation for acute lymphoblastic leukemia." 117 : 238-244, 1990

8 Odame I, "Osteopenia, physical activity and health-related quality of life in survivors of brain tumors treated in childhood." 46 : 357-362, 2006

9 Krishnamoorthy P, "Osteopenia in children who have undergone posterior fossa or craniospinal irradiation for brain tumors." 158 : 491-496, 2004

10 Barr R.D, "Osteopenia in children surviving brain tumours." 34 : 873-877, 1998

11 Rood B.R, "Macdonald TJ, Packer RJ. Current treatment of medulloblastoma: recent advances and future challenges." 31 : 666-675, 2004

12 Brumsen C, "Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis." 76 : 266-283, 1997

13 Falcini F, "Intravenous administration of alendronate counteracts the in vivo effects of glucocorticoids on bone remodeling." 58 : 166-169, 1996

14 McNeil D.E, "Incidence and trends in pediatric malignancies medulloblastoma/ primitive neuroectodermal tumor: a SEER update. Surveillance Epidemiology and End Results." 39 : 190-194, 2002

15 Clarson C.L, "Growth failure after treatment of pediatric brain tumors." 103 : 37-42, 1999

16 Gurney J.G, "Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors: Childhood Cancer Survivor Study." 97 : 663-673, 2003

17 Glorieux F.H, "Cyclic administration of pamindronate in children with severe osteogenesis imperfecta." 339 : 947-952, 1998

18 Homik J.E, "A meta-analysis on the use of bisphosphonates in corticosteroid induced osteoporosis." 26 : 1148-1157, 1999